Anteris Technologies Limited advised that the early results from the first-in-human study of its proprietary DurAVR aortic valve found that patient outcomes exceeded the results of what is normally expected following a Surgical Aortic Valve Replacement (SAVR). The DurAVR valve was easy to manipulate and was able to be optimally positioned by the implanting surgeon in the aortic valve replacement procedures, promoting better results. Professor Bart Meuris MD, PhD - Chief of Cardiovascular Surgery at University Hospitals, Leuven (Belgium) and lead surgeon in the study - presented the findings at the European Association for Cardio-Thoracic Surgery (EACTS) Annual Conference, a world premier cardio-thoracic conference held on 8-10 October 2020. The presentation noted: DurAVR can restore normal pre-disease hemodynamics and has the potential to be a functional cure for the treatment of severe aortic stenosis; Patient recovery was swift, and no stay in an intensive care unit was needed; Ongoing development continues, including animal studies for transcatheter heart valve replacement; This technology, with both surgical and transcatheter options, offers a potentially more durable solution for enhancing acute and long-term outcomes for patients with aortic valve disease.